0001799191-26-000010
SEC filingRevenue surged 41.2% to $147.4M from specialty pharmacy growth, narrowing operating loss 34.3% to -$6.5M and net loss 87.3% to -$2.5M, though negative margins and cash burn persist amid higher capex and liquidity risks.
Revenue grew 41.2% to $147.4 million in Q1 FY2026 from $104.4 million in the prior year quarter, primarily driven by expansion in the specialty pharmacy segment. This topline acceleration reflects higher volume in oral medications dispensed at TOI professional corporations' clinic locations, supporting the company's value-based oncology care model despite pricing dynamics.
Net income loss improved dramatically 87.3% to -$2.5 million from -$19.6 million, with diluted EPS at -$0.02 versus -$0.21. This reflects the operating progress alongside other income statement dynamics.
Liquidity remains a focus, with management stating current capital sources suffice for near-term needs but cautioning no assurance for future requirements. If funds prove insufficient, the company may need to cut operating and capital expenses substantially or pursue restructuring, potentially impacting business operations and strategy execution. These dynamics underscore the balance between growth investments and path to profitability in oncology care delivery.